Review
Medicine, General & Internal
Wei Li, Li Wan, Shaojun Duan, Jingjing Xu
Summary: This study explores the current status and trends in TLR agonists research through bibliometric analysis. The research shows that the majority of TLR agonists research is conducted in the United States, and there have been changes in research hotspots and trends. This study provides researchers with an overview of TLR agonists research.
Review
Oncology
Sainiteesh Maddineni, Michelle Chen, Fred Baik, Vasu Divi, John B. Sunwoo, Andrey Finegersh
Summary: A meta-analysis of existing clinical trials for recurrent and metastatic head and neck cancer found that Toll-like receptor agonists do not provide additional clinical benefits and do not increase adverse events in the treatment of this cancer. Future clinical trials may need to focus on new agents or drug combinations.
Review
Immunology
Samik Chakraborty, Juan Ye, Herui Wang, Mitchell Sun, Yaping Zhang, Xueyu Sang, Zhengping Zhuang
Summary: This review discusses the application and challenges of using Toll-like receptor (TLR) agonists as immunoadjuvants in cancer immunotherapy. Several studies have demonstrated the efficacy of TLR agonists as immunotherapy strategies, including monotherapy and combination therapy. The use of TLR agonists as adjuvants for cancer vaccines is a current focus of research.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Arshpreet Kaur, Jeremy Baldwin, Deshkanwar Brar, Deepak B. Salunke, Nikolai Petrovsky
Summary: The development of new human adjuvants has been revolutionized by the discovery of toll-like receptors (TLRs), leading to a better understanding of their mechanisms of action. This work has important implications for the development of vaccines and immunotherapies against various diseases.
CURRENT OPINION IN CHEMICAL BIOLOGY
(2022)
Article
Toxicology
Menno Grouls, Meike van der Zande, Laura de Haan, Hans Bouwmeester
Summary: In various in vitro intestinal models, exposure to flagellin triggered an increase in IL-8 secretion as a pro-inflammatory response, while other TLR agonists did not induce a similar response, suggesting a lack of presence or functionality of specific TLRs in these models.
TOXICOLOGY IN VITRO
(2022)
Article
Oncology
Taku Kimura, Ken-ichiro Sakata, Jun Sato, Chisato Ouchi, Noritaka Ohga, Aya Yanagawa-Matsuda, Kyoko Hida, Yoshimasa Kitagawa
Summary: Metastatic basal cell carcinoma poses challenges in current treatment and requires consideration of treatment history and pathohistological features in posttreatment planning.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Mohammad Enamul Hoque Kayesh, Michinori Kohara, Kyoko Tsukiyama-Kohara
Summary: Chronic hepatitis B virus (HBV) infection is a major global health problem, and the link between Toll-like receptors (TLRs) and chronic HBV infection is being increasingly recognized. TLR agonists have the potential to enhance the host immune response against HBV infection and improve CHB treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Pharmacology & Pharmacy
Hong Liang, William R. Lykins, Emilie Seydoux, Jeffrey A. Guderian, Tony Phan, Christopher B. Fox, Mark T. Orr
Summary: Adjuvants are important in vaccine formulations and can activate TLR4, including phospholipid DMPC. These findings may have implications for off-target immune responses in pharmaceutical development.
Article
Chemistry, Multidisciplinary
Bao Loc Nguyen, Cao Dai Phung, Duc-Vinh Pham, Ngoc Duy Le, Jee-Heon Jeong, Jeonghwan Kim, Ju-Hyun Kim, Jae-Hoon Chang, Sung Giu Jin, Han -Gon Choi, Sae Kwang Ku, Jong Oh Kim
Summary: The researchers designed a liposomal nanoparticle platform that delivers toll-like receptor 7 and toll-like receptor 3 agonists simultaneously to enhance the immunogenic condition of the tumor microenvironment in triple-negative breast cancer (TNBC). The treatment effectively inhibited tumor growth in mice and showed potential for combination therapy with immune checkpoint inhibitors.
JOURNAL OF CONTROLLED RELEASE
(2023)
Article
Chemistry, Medicinal
Richard C. Hewer, Louisa A. Christie, Kevin J. Doyle, Xiao Xu, Maxine J. Roberts, Louise Dickson, Toni Cheung, David H. Cadwalladr, Philip Pickford, Martin Teall, Justin A. C. Powell, Steven Sheardown, Lakshminarayana Narayana, Nicola L. Brice, Lee A. Dawson, Mark Carlton, Roland W. Burli
Summary: Based on our transcriptomics data, we identified GPR55 as a potential target for treating motor symptoms in Parkinson's disease. Through screening, we found compounds with high potency as agonists for both human and rat GPR55. These compounds demonstrated biased signaling and were selective over other cannabinoid receptors. This study provides insights into the role of GPR55 in the brain.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Farideh Sadeghkhani, Zahra Hajihassan, Sajjad Gharaghani
Summary: This study identified two potential TLR8 agonists with favorable pharmacological features, which could be used for future experimental studies. The compounds showed advantages over Motolimod, and their flexibility and energy levels were compared to provide insights for further research.
JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
(2023)
Review
Pharmacology & Pharmacy
Lingling Huang, Xiaoyan Ge, Yang Liu, Hui Li, Zhiyue Zhang
Summary: Toll-like receptor agonists (TLRa) as vaccine adjuvant candidates have become a hot topic in cancer immunomodulation research. However, current systemic deliveries of TLRa have limitations, and TLRa-loaded nanoparticles are considered a promising strategy to improve therapeutic outcomes.
Review
Biochemistry & Molecular Biology
Luca Di Bartolomeo, Federico Vaccaro, Natasha Irrera, Francesco Borgia, Federica Li Pomi, Francesco Squadrito, Mario Vaccaro
Summary: Canonical and non-canonical Wnt signaling pathways play a significant role in cutaneous carcinogenesis, including modulating the tumor microenvironment, synergizing with the Sonic Hedgehog pathway, and promoting tumor progression and the epithelial-mesenchymal transition. Targeting Wnt pathways could be a promising approach for managing non-melanoma skin cancer patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Biochemistry & Molecular Biology
Irene Veneziani, Claudia Alicata, Lorenzo Moretta, Enrico Maggi
Summary: Toll-like receptors (TLRs) are pattern recognition receptors (PRRs) that activate innate immunity by recognizing pathogens. They are found on tumor cells, tumor microenvironment (TME) cells, and natural killer (NK) cells. TLRs on the cell surface recognize extracellular ligands, while TLRs in endosomes recognize microbial DNA or RNA. Engagement of TLRs activates intracellular pathways, leading to the production of inflammatory molecules. Endosomal TLR agonists have been shown to modify the TME and may be used as immunotherapeutic adjuvants to improve anti-tumor immunity.
Article
Engineering, Biomedical
Joo Hang Lee, Jihyeon Song, In Gyu Kim, Gayeon You, Han Kim, Joong-Hoon Ahn, Hyejung Mok
Summary: In this study, combination therapy using a TGF beta RI kinase inhibitor and TLR 7/8 agonist encapsulated within EXOs was shown to be effective in treating melanoma and prostate cancer. The therapy reduced tumor migration and triggered the release of proinflammatory cytokines, leading to reduced tumor growth and improved survival rate.
ACTA BIOMATERIALIA
(2022)